3 citations
,
July 2024 in “Archives of Dermatological Research” This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
4 citations
,
January 2020 in “PubMed” This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.
January 2026 in “Journal of Clinical Medicine” The study found that systemic inflammatory markers were elevated in patients with severe alopecia areata compared to those with mild disease and healthy controls, and these markers decreased in patients who improved after JAK inhibitor therapy.